NanoRepro AGXTER:NN6 63 OCF Margin % is 71.84% as of Jun. 2025. GuruFocus rates XTER:NN6 with a GF Score™ of 63/100 and a GF Value™ of €1.01 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, NanoRepro AG ranks better than 97.54% on this metric.
The historical rank and industry rank for NanoRepro AG's OCF Margin % or its related term are showing as below:
XTER:NN6'
s OCF Margin % Range Over the Past 10 Years
Min: -316.11 Med: -29.88 Max: 212.13
Current: 39.83
During the past 13 years, the highest OCF Margin % of NanoRepro AG was 212.13%. The lowest was -316.11%. And the median was -29.88%.
XTER:NN6's OCF Margin % is ranked better than 97.54% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.67
vs XTER:NN6: 39.83
NanoRepro AG OCF Margin % Related Terms
NanoRepro AG OCF Margin % Historical Data
* Premium members only.
The historical data trend for NanoRepro AG's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:NN6 vs TMO, DHR, IDXX: OCF Margin % Comparison
For the Diagnostics & Research subindustry, NanoRepro AG's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NanoRepro AG OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NanoRepro AG's OCF Margin % distribution charts can be found below:
* The bar in red indicates where NanoRepro AG's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NanoRepro AG (XTER:NN6) has a OCF Margin % of 71.84% as of Jun. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on NanoRepro AG and its competitors. According to the industry distribution chart, NanoRepro AG ranks #5 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 2.5%.
Is NanoRepro AG's OCF Margin % too high?
NanoRepro AG's current OCF Margin % is 71.84%. The Medical Diagnostics & Research industry median OCF Margin % is 4.67. NanoRepro AG's value of 71.84% is 1438.3% above this industry median. Based on the distribution chart, NanoRepro AG ranks #5 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, NanoRepro AG has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NanoRepro AG's OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, NanoRepro AG ranks #5 out of 203 companies for OCF Margin %. This places NanoRepro AG in the top 3% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 4.67. NanoRepro AG's value of 71.84% is 1438.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.67, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NanoRepro AG's current OCF Margin % of 71.84% is 1438.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on NanoRepro AG and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NanoRepro AG's current OCF Margin % is 71.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NanoRepro AG stock overvalued right now?
Based on GuruFocus' analysis, NanoRepro AG (XTER:NN6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.01, compared to a current price of €2.08 — trading 105.9% above its estimated fair value. The current OCF Margin % is 71.84% and 1438.3% above the Medical Diagnostics & Research industry median of 4.67. NanoRepro AG's overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For NanoRepro AG (XTER:NN6), the current OCF Margin % is 71.84% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NanoRepro AG (XTER:NN6) Overvalued in 2026?
Based on GuruFocus' analysis, NanoRepro AG stock appears to be overvalued.
The current stock price of €2.08 is trading 105.9% above its estimated GF Value™ of €1.01.
GuruFocus considers NanoRepro AG to be Significantly Overvalued.
Key valuation signals for XTER:NN6:
OCF Margin %: 71.84%
GF Value™: €1.01 vs. price of €2.08 (105.9% above fair value)
Industry Position: 1438.3% above the Medical Diagnostics & Research median (#5 of 203)
No single metric tells the full story. See the XTER:NN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
63GF Score
Get the complete analysis for XTER:NN6
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:NN6 has been successfully added to your 
